Evercore ISI initiated coverage of Summit Therapeutics (SMMT) with an Outperform rating and $30 price target The firm sees lead asset, ...
Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...
16don MSN
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...
Merck & Co's FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival in these patients. Keytruda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results